Azienda Sanitaria Territoriale Di Macerata - Ospedale Civitanova Marche
- Address
- Via Pietro Ginevri 1, 62012 Civitanova Marche, Italy
Congenital and Hereditary Diseases
At Azienda Sanitaria Territoriale Di Macerata - Ospedale Civitanova Marche, research in congenital and hereditary diseases focuses on hereditary angioedema, a condition that can cause sudden swelling attacks and affect daily life. The clinical trial work here is aimed at evaluating a new preventive treatment and understanding its long-term safety and tolerability.
- Studying hereditary angioedema to improve ongoing prevention of attacks
- Assessing the safety and tolerability of a potential long-term treatment approach
- Supporting better disease control for adults and adolescents living with this rare condition
This area reflects a strong interest in rare disease care, with research designed to help patients manage symptoms more effectively over time.
Neoplasms
The site also conducts clinical research in neoplasms, with a focus on acute myeloid leukemia, a serious blood cancer that requires carefully selected treatment options. The trial activity is centered on testing whether adding a new therapy can improve outcomes for adults who are newly diagnosed and unable to receive intensive chemotherapy.
- Investigating acute myeloid leukemia with a specific genetic change
- Evaluating whether a new treatment combination can improve survival and remission rates
- Advancing treatment options for patients with limited standard therapy choices
This research highlights the center’s involvement in oncology studies that aim to improve treatment effectiveness and support better outcomes in challenging leukemia cases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Pharvaris Netherlands B.V.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pharvaris Netherlands B.V.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Territoriale Di Macerata - Ospedale Civitanova Marche
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Gemtuzumab Ozogamicin with Chemotherapy on Minimal Residual Disease in Adult Patients with Favorable-Intermediate-Risk Acute Myeloid Leukemia | Fondazione Gimema Franco Mandelli Onlus | Phase III | Recruiting | Sep 2020 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide | 1 | Unknown | 2022-04-29 | 2022-04-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.